PredictImmune is developing pioneering tools to guide physicians in the treatment of patients with immune-mediated disease, through prediction of long-term clinical prognosis.
The company is currently developing its first product, a prognostic biomarker test, to address inflammatory bowel disease (both Crohn’s and ulcerative colitis).
The technology, based on world-leading research emanating from the University of Cambridge, accurately identifies patients – at diagnosis – who are at risk of experiencing severe, relapsing disease and therefore likely to benefit from early biologics therapy.
PredictImmune raised £4.7m Series A funding in May 2017 led by Parkwalk Opportunities Fund with co-investment from Cambridge Enterprise and Wren Capital. It recently secured an additional £4.3 million investment from the Wellcome Trust to support a prospective multi-centre clinical trial of the prognostic biomarker test.